Introduction {#sec1-1}
============

*Veerataru* is the first drug of the *Veeratarvadigana* coined from its name; the drug has not achieved considerable recognition in Ayurvedic clinical practice until now. It has wide spread use in folk and tribal medicine. In Sushrutasamhita much emphasis has been given on *Veerataru* to treat *Mootrakruchchhra*, *Mootraghata*, *Ashmari*, *Vatavyadhi* etc., in *Veeratarvadi gana*.\[[@ref1]\] *Mootrakruchchhra* is a disease of *Basti*. It comes under *Mootraapravrittijanyavyadhi*, where *Kruchchhrata* (Shoola and Daha) during *Mootrapravritti* is the chief symptom.\[[@ref2]\]

The clinical evaluation of the drug *Veerataru* in *Mootrakruchchhra* is specially focused on Ayurvedic basis. Relevant observation of modern investigations like blood urea, Serum creatinine (S. creatinine), Serum calcium (S. calcium), Serum uric acid (S. uric acid) etc., was considered as supportive tools. Main aim of present study was to explore clinically the lesser-known utilized drug *Veerataru*. As the drug requires scientific validation for its efficacy on *Mootrakruchchhra*, the drug was subjected for clinical study to evaluate its therapeutic effect described in classics.

Materials and Methods {#sec1-2}
=====================

Total 66 clinically diagnosed and confirmed cases of *Mootrakruchchhra* completed the current trial. The cases were selected from Inpatient Department and Outpatient Department of *Dravyaguna*, Institute for Post Graduate Teaching and Research in Ayurveda Hospital, Jamnagar. Specially prepared proforma was used to evaluate the patients during the study and follow up. Patients having clinical features of *Mootrakruchchhra*, aged above 5 years were included in to the trial. Patients having any anatomical defects in kidney, ureters and bladder (KUB), diabetic or cardiac patients, and patients having other severe systemic disorders or the condition where the symptoms manifests as a complication of other diseases like *Arbuda* (Tumor), gonorrhea, thread worms infection, hysteria etc., were excluded. In the patients of both the group routine urine examination, ultrasound abdomen X-ray KUB and hematological, biochemical investigations (*S. creatinine*, uric acid, *S. calcium*, blood urea) were carried out before and after completion of the treatment.

Administration of drugs {#sec2-1}
-----------------------

66 patients of *Mootrakruchchhra* were randomly divided in two following two groups.

### Group A (trial group) {#sec3-1}

35 patients were administered with *Kwatha* (Decoction) form of *Veerataru* (made by 15 g. of Yavakut Churna) for 21 days, twice daily.

### Group B (standard control group) {#sec3-2}

31 patients were administered with *Kwatha* (Decoction) form of *Punarnava* (*Boerhaavia diffusa* Linn.) made by 15 g. of *Yavakut Churna* for 21 days, twice daily. Patients were advised to avoid *Ativyayam*, *Madyapan*, *Tikshna Ahara* and *Aushadha*, *Anupa Mamsa Sevana*, *Adhyashana*, *Ajirnashana* and *Drutgati Yana*.

Criteria of assessment {#sec2-2}
----------------------

All the patients registered for the current study were assessed on following parameters before and after the course of therapy to work out the efficacy of the treatment produced in the patients of both groups.

### A: Subjective improvement {#sec3-3}

A specific rating scale for subjective parameters was utilized to assess the efficacy of the therapy. Changes found in signs and symptoms like *Sashoola* (painful micturation), *Sadaha* (burning micturation), *Abhikshna* (increased frequency) and *Alpamootrapravrutti* (Oliguria) related to *Mootrakruchchhra* were analyzed statistically.

### B: Pathological and biochemical changes {#sec3-4}

The results were assessed based on the changes observed in biochemical and pathological parameters.

Criteria for overall assessment of therapy {#sec2-3}
------------------------------------------

The total effect of therapy was assessed considering overall improvement in signs and symptoms derived by following formula:

Complete remission: 100% reliefMarked improvement: \>75% reliefModerate improvement: 50-75% reliefMild improvement: 25-50% reliefUnchanged: \<25% or no relief.

Statistical analysis {#sec2-4}
--------------------

The information gathered based on observation made about various parameters was subjected to statistical analysis in terms of mean, standard deviation and standard error. *t*-test was carried out and calculated values are compared with t table value at *P* \< 0.05, *P* \< 0.01, *P* \< 0.001 to find out the level of significance. The obtained results were interpreted as Insignificant: *P* \>0.05, significant: *P* \<0.05, highly significant: *P* \<0.01, *P* \< 0.001.

Results {#sec1-3}
=======

Effect of therapy on *Sashoolmootrapravrutti* {#sec2-5}
---------------------------------------------

In Group A, the relief reported by the patients for pre, during and post-*Sashoolamootrapravritti* was 68.18%, 79.41% and 83.33% respectively. In Group B, the relief got by the patients for pre, during and post-*Sashoolamootrapravritti* was 51.61%, 58.20% and 63.15% respectively. The effect of the therapy of both the drugs on *Shoola* was found to be statistically highly significant, though the test drug was slightly more effective than the standard control \[[Table 1](#T1){ref-type="table"}\].

###### 

Effect of therapy on *Sa-Shoolamootrapravrutti*

![](AYU-34-249-g001)

Effect of therapy on *Sadahamootrapravrutti* {#sec2-6}
--------------------------------------------

Relief noted by the patients in Group A for pre, during and post-*Sadahamootrapravritti* was 87.50%, 59.40% and 83.33% respectively. In Group B for pre, during and post-*Sadahamootrapravritti* was 52.77%, 38.67% and 39.13% respectively. The effect of the therapy of both the drugs on Daha was found to be statistically highly significant, though the test drug was slightly more effective than the standard control \[[Table 2](#T2){ref-type="table"}\].

###### 

Effect of therapy on *Sa-Dahamootrapravrutti*
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Effect of therapy on *Alpa* and *Abhikshanamootrapravrutti* {#sec2-7}
-----------------------------------------------------------

Data shows that 92.30% and 70.59% relief was found in *Alpa* (Oligouria) and *Abhikshana* (increased frequency) *Mootrapravritti* respectively in group A Whereas 86.96% and 72.41% in Group B. the effect of the therapy of both the drugs on *Alpa* and *Abhikshana Mootrapravritti* was found to be statistically highly significant, though the effect of standard control drug was slightly more effective than the test drug \[[Table 3](#T3){ref-type="table"}\].

###### 

Effect of therapy on *Alpa* and *Abhikshna mootra pravrutti*
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Total effect on the patients of *Mootrakruchchhra* {#sec2-8}
--------------------------------------------------

The data regarding the total effect of the therapy by the both groups are shown in above table in Group A. 45.71% patients observed marked improvement, 37.14% patients observed moderate improvement, 11.42% observed complete remission from the disease while 5.71% observed mild improvement while in Group B, 41.93% patients showed moderate and mild improvement, 9.67% patients showed marked improvement, 3.22% showed completed remission from the disease while 3.22% remained unchanged, i.e. showed no improvement \[[Table 4](#T4){ref-type="table"}\].

###### 

Total effect on the patients of *Mootrakruchchhra*
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Pathological investigation {#sec2-9}
--------------------------

In Group A erythrocyte sedimentation rate (ESR) decreased by 6.40% while monocyte count decreased by 3.67% but there was no changes in Group B which was statistically significant. No remarkable changes were found in other pathological parameters. In Group B, total count decreased by 1.72%, differential count decreased by 2.67%, monocytes decreased by 8.16% while ESR decreased by 5.55%. Eosinophils increased by 18% whereas hemoglobin increased by 1.12%. This increase and decrease was within normal range except ESR and the changes were statistically non-significant \[Tables [5](#T5){ref-type="table"} and [6](#T6){ref-type="table"}\].

###### 

Group A effect of therapy on pathological investigations
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###### 

Group B effect of therapy on pathological investigations

![](AYU-34-249-g006)

Biochemical investigation {#sec2-10}
-------------------------

In Group A, blood urea decreased by 6.41% whereas S. creatinine, S. calcium and uric acid increased by 5.73%, 1.20% and 6.92%. The changes were within the normal range except blood urea but the changes were not statistically significant. In Group B, there were no significant or remarkable changes found in biochemical parameters except 7.57% decrease in blood urea which was a significant decrease at *P* \< 0.05 \[Tables [7](#T7){ref-type="table"} and [8](#T8){ref-type="table"}\].

###### 

Group A effect of therapy on biochemical investigations
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###### 

Group B effect of therapy on biochemical investigations
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Overall effect of therapy on all symptoms of patients {#sec2-11}
-----------------------------------------------------

The overall effect on all symptoms of the patients was found in Group A 80.91% and 73.68% was found in Group B, both the results were statistically highly significant \[[Table 9](#T9){ref-type="table"}\].

###### 

Overall effect of therapy on all symptoms of patients
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Discussion {#sec1-4}
==========

In Group A the drug has shown pronounced effect in relieving *Shoola*. Vitiated *Vata* (*Apanavata Vaigunys*)\[[@ref3]\] is main causative factor for *Shoola*. The drug *Veerataru* is effective on *Vatadosha* due to its *Ushnaveerya*. The same is reflected in the actions quoted for the drug by Bhavaprakashnighantu in *Guduchyadivarga*\[[@ref4]\] 302/3 as *Anilartijita* and *Rajanighantu* in *Shalmalyadi Varga*\[[@ref5]\] 71-72 as *Vatamayavinashanaha*. *Daha* was relieved more effectively in the patients of Group A. *Daha* is due to the predominance of *Pitta*. According to Acharya Kashyapa, *Pitta* acts as the chief causative factor in the pathogenesis of *Mootrakruchchhra*.\[[@ref6]\] The drug, due to its *Tiktarasa* acts as *Pittashamaka*. *Tiktarasa* is said to be first among the three *Rasas*, which alleviates *Pittadosha*.\[[@ref7]\] The symptoms namely *Alpa* and *Abhikshanamootrapravrutti* were relieved significantly in group A. The symptoms are mainly due to *Pratilomatva* of *Vata*\[[@ref8]\] and the drug *Veerataru* is also said to be *Vatamayavinashana*.\[[@ref9]\] Besides, the drug is attributed with the property of *Mootravirekakara* by *Ashtanga Samgrahakara*.\[[@ref9]\]

Conclusion {#sec1-5}
==========

From the clinical study, it has been observed that *Veerataru Kwatha* is effective on most of the cardinal symptoms of *Mootrakruchchhra* and statistically highly significant effect was observed.
